Lupin gets EIR from US FDA for its API manufacturing facility in Vizag

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

77
USFDA Inspection audit
USFDA Inspection

Last Updated on January 5, 2024 by The Health Master

Global pharma major Lupin Limited (Lupin) announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its API manufacturing facility located in Visakhapatnam (Vizag), India.

The EIR was issued post the last inspection of the facility conducted from March 6 to March 10, 2023.

The inspection closed with the facility receiving an inspection classification of “No Action Indicated” (NAI).

“We are happy to have received the EIR for our Vizag facility from the USFDA,” said Nilesh Gupta, managing director, Lupin.”

““We remain committed to ensuring the high quality of our products and ensuring the safety of our manufacturing processes.”

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news